Vimal Mehta - Jul 22, 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: CEO and President, Director
Signature: /s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D.
Stock symbol: BTAI
Transactions as of: Jul 22, 2025
Transactions value $: $0
Form type: 4
Date filed: 7/22/2025, 08:29 PM
Previous filing: Jun 16, 2025
Next filing: Aug 5, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Mehta Vimal	CEO and President, Director	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN	/s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D.	2025-07-22	0001733369

Transactions Table

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Ownership	Footnotes
transaction	BTAI	Common Stock	Award	+15.6K	+348.31%	20.1K	Jul 22, 2025	Direct	F1
holding	BTAI	Common Stock				125	Jul 22, 2025	By Spouse
holding	BTAI	Common Stock				480K	Jul 22, 2025	By BioXcel LLC	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 15,625 PSUs had been satisfied and 15,625 shares of common stock became issuable to the Reporting Person on July 22, 2025.
F2	These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Content

The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 15,625 PSUs had been satisfied and 15,625 shares of common stock became issuable to the Reporting Person on July 22, 2025.

These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.